The BMJ, November 23, 2015. A controversial proposed new health law would have had a terrible impact on the lives of Alzheimer’s patients and their families, who would have spent billions on medications that don’t work and can cause cancer.
Read More »On Health Policy
Comments on Nondiscrimination in Health Programs and Activities
November 9, 2015. We fully support the Administration’s efforts to “prohibit discrimination on the basis of race, color, national origin, sex, age, or disability in certain health programs and activities.”
Read More »NCHR Testimony at FDA Meeting on Risk Evaluation and Mitigation Strategies (REMS)
October 5, 2015. Our Center strongly supports research and programs to improve drug safety. We remember when REMS were first proposed in legislation, the reason was to enable FDA to approve drugs with serious risks by providing a mechanism to mitigate those risks.
Read More »NCHR at FDA Meeting on Essure Contraceptive
September 24, 2015. If the product is to be on the market, who should do the studies to accurately determine the short-term and long-term effectiveness and side effects? The company’s track record and response to the women’s reported complications is not acceptable. Any additional research should be conducted independently of the company so that patients can have confidence in its accuracy.
Read More »Comments to the U.S. Consumer Product Safety Commission Regarding Supplemental Mattresses
October 13, 2015. The National Center for Health Research supports Keeping Babies Safe’s (KBS) petition that requests a ban on supplemental mattresses for play yards with non-rigid sides. These mattresses present an unreasonable risk of injury or death (suffocation) to infants and toddlers.
Read More »